epz-6438 and dinaciclib

epz-6438 has been researched along with dinaciclib* in 1 studies

Other Studies

1 other study(ies) available for epz-6438 and dinaciclib

Article	Year
CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer. Nature communications, 2019, 11-08, Volume: 10, Issue:1 Topics: Animals; Benzamides; Biphenyl Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cyclic N-Oxides; Cyclin-Dependent Kinase 2; Enhancer of Zeste Homolog 2 Protein; Estrogen Receptor alpha; Female; Humans; Indolizines; Mammary Glands, Human; Mammary Neoplasms, Experimental; Mice; Mice, Transgenic; Morpholines; Phosphorylation; Pyridinium Compounds; Pyridones; Receptor, ErbB-2; Receptors, Progesterone; Triple Negative Breast Neoplasms	2019

Article

Year

CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer.

Nature communications, 2019, 11-08, Volume: 10, Issue:1

Topics: Animals; Benzamides; Biphenyl Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cyclic N-Oxides; Cyclin-Dependent Kinase 2; Enhancer of Zeste Homolog 2 Protein; Estrogen Receptor alpha; Female; Humans; Indolizines; Mammary Glands, Human; Mammary Neoplasms, Experimental; Mice; Mice, Transgenic; Morpholines; Phosphorylation; Pyridinium Compounds; Pyridones; Receptor, ErbB-2; Receptors, Progesterone; Triple Negative Breast Neoplasms

2019